首页|A Randomized Trial of Intravenous Amino Acids for Kidney Protection
A Randomized Trial of Intravenous Amino Acids for Kidney Protection
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
Background:Acute kidney injury (AKI) is a serious and common complication of cardiac surgery,for which reduced kidney perfusion is a key contributing factor. Intravenous amino acids increase kidney perfusion and recruit renal functional reserve. However,the efficacy of amino acids in reducing the occurrence of AKI after cardiac surgery is uncertain.Methods:In a multinational,double-blind trial,we randomly assigned adult patients who were scheduled to undergo cardiac surgery with cardiopulmonary bypass to receive an intravenous infusion of either a balanced mixture of amino acids,at a dose of 2 g per kilogram of ideal body weight per day,or placebo (Ringer's solution) for up to 3 days. The primary outcome was the occurrence of AKI,defined according to the Kidney Disease:Improving Global Outcomes creatinine criteria. Secondary outcomes included the severity of AKI,the use and duration of kidney-replacement therapy,and all-cause 30-day mortality.Results:We recruited 3511 patients at 22 centers in three countries and assigned 1759 patients to the amino acid group and 1752 to the placebo group. AKI occurred in 474 patients (26.9％) in the amino acid group and in 555 (31.7％) in the placebo group (relative risk,0.85;95％ confidence interval[CI],0.77 to 0.94;P=0.002). Stage 3 AKI occurred in 29 patients (1.6％) and 52 patients (3.0％),respectively (relative risk,0.56;95％ CI,0.35 to 0.87). Kidney-replacement therapy was used in 24 patients (1.4％) in the amino acid group and in 33 patients (1.9％) in the placebo group. There were no substantial differences between the two groups in other secondary outcomes or in adverse events.Conclusions:Among adult patients undergoing cardiac surgery,infusion of amino acids reduced the occurrence of AKI.
NETL
NSTL
万方数据
